The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh, MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS, University College London Hospitals, London, UK, briefly comments on the increased risk of thrombosis and cardiovascular (CV) events in patients with myeloproliferative neoplasms (MPNs). Dr Ghosh highlights a study that aimed to modify traditional risk-scoring algorithms to consider disease-specific factors and avoid underestimating CV risk in patients. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
